Alvotech hlýtur markaðsleyfi í Bandaríkjunum fyrir Selarsdi (ustekinumab-aekn) líftæknilyfjahliðstæðu við Stelara
16 avr. 2024 17h30 HE
|
Alvotech
Markaðsleyfið er fyrir notkun lyfsins til meðferðar bæði á fullorðnum og börnum Þetta er önnur líftæknilyfjahliðstæða Alvotech sem hlýtur markaðsleyfi í Bandaríkjunum Gert er ráð fyrir að Selarsdi...
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
16 avr. 2024 17h30 HE
|
Alvotech
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva SELARSDI is expected to be marketed in the...
Alvotech tilkynnir um útgáfu eigin hlutabréfa
22 mars 2024 16h15 HE
|
Alvotech
Alvotech (NASDAQ: ALVO) tilkynnti í dag að stjórn fyrirtækisins hefði ákveðið að gefa út þrettán milljón (13.000.000) nýja almenna hluti í félaginu. Dótturfélag Alvotech, Alvotech Manco ehf....
Alvotech Announces Increase in Number of Own Shares
22 mars 2024 16h15 HE
|
Alvotech
Alvotech (NASDAQ: ALVO) (the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, has increased the Company´s share...
Alvotech birtir uppgjör fyrir árið 2023 og kynnir nýjustu áfanga í rekstri félagsins
20 mars 2024 16h15 HE
|
Alvotech
Heildartekjur á árinu 2023 voru 93,4 milljónir dollara, sem er 10% aukning frá fyrra áriSölutekjur á árinu 2023 voru 48,7 milljónir dollara, samanborið við 24,8 milljónir dollara á árinu 2022, og voru...
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
20 mars 2024 16h15 HE
|
Alvotech
Total Revenues in 2023 were $93.4 million, up 10% from previous yearProduct Revenues in 2023 were $48.7 million, compared to $24.8 million in 2022, with Q4 2023 product revenues of $18.9 million, up...
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
20 mars 2024 16h15 HE
|
Alvotech
Total Revenues in 2023 were $93.4 million, up 10% from previous yearProduct Revenues in 2023 were $48.7 million, compared to $24.8 million in 2022, with Q4 2023 product revenues of $18.9 million, up...
Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET
05 mars 2024 16h00 HE
|
Alvotech
REYKJAVIK, Iceland, March 05, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients...
Alvotech skipar nýjan framkvæmdastjóra gæðamála
29 févr. 2024 16h05 HE
|
Alvotech
Alvotech (NASDAQ: ALVO) tilkynnti í dag að Christina Siniscalchi hafi verið skipuð tímabundið í stöðu framkvæmdastjóra gæðamála. Christina tekur við af Söndru Casaca, sem lætur af starfi sem liður í...
Alvotech Appoints Interim Chief Quality Officer
29 févr. 2024 16h05 HE
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Christina Siniscalchi will join...